olivacine has been researched along with Lung Neoplasms in 3 studies
*Lung Neoplasms: Tumors or cancer of the LUNG. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Archer, S; el-Hamouly, W; Modi, SP; Portuese, E; Ruckdeschel, JC | 1 |
| Gąsiorowski, K; Gębarowski, T; Gębczak, K; Tylińska, B; Wiatrak, B | 1 |
| Atassi, G; Bisagni, E; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D; Visalli, M | 1 |
3 other study(ies) available for olivacine and Lung Neoplasms
| Article | Year |
|---|---|
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbamates; Ellipticines; Humans; Leukemia L1210; Lung Neoplasms; Mice; Structure-Activity Relationship; Tumor Cells, Cultured | 1992 |
Effect of new olivacine derivatives on p53 protein level.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; BALB 3T3 Cells; Cell Line, Tumor; Ellipticines; Humans; Lung Neoplasms; Mice; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Suppressor Protein p53 | 2020 |
In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Breast Neoplasms; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Ellipticines; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia P388; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured | 1996 |